Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rocket Pharmaceuticals (DE:9IP1)
FRANKFURT:9IP1
Holding DE:9IP1?
Track your performance easily
9IP1 Stock Chart & Stats
Day’s Range― - ―
52-Week Range€9.36 - €28.41
Previous CloseN/A
Volume0.00
Average Volume (3M)1.00
Market Cap
$1.12B
Enterprise Value€1.53B
Total Cash (Recent Filing)$126.47M
Total Debt (Recent Filing)$48.96M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Mar 06, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.54
Shares Outstanding106,337,080
10 Day Avg. Volume0
30 Day Avg. Volume1
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.90
P/FCF Ratio0.00
Enterprise Value/Market Cap1.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-664.82
Enterprise Value/Ebitda-6.09
Forecast
1Y Price Target
€41.26Price Target Upside319.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Rocket Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessAll Ph1 patients met the pivotal Ph2 primary endpoint, achieving normalized Hgb levels and requiring no more RBC transfusions up to 36 months after RP-L301 infusion.
Positive Data And MomentumEncouraging long-term Phase 1 data strengthens positive momentum for Rocket Pharma.
Regulatory ApprovalRCKT has aligned with the FDA on an accelerated approval pathway for RP-L301.
Bears Say
Approval DelaysApproval for leukocyte adhesion deficiency type I treatment has been delayed to 2025, impacting financial expectations.
Financial PerformanceUpdating the model for the offering lowers the price target from $44 to $40.
Operational ChallengesInitiation of RP-L301's pivotal study has been delayed until 2025.
---
Options Prices
Currently, No data available
---
Ownership Overview
34.67% Insiders
22.53% Mutual Funds
0.17% Other Institutional Investors
31.24% Public Companies and Individual Investors
9IP1 FAQ
What was Rocket Pharmaceuticals’s price range in the past 12 months?
Rocket Pharmaceuticals lowest stock price was €9.36 and its highest was €28.41 in the past 12 months.
What is Rocket Pharmaceuticals’s market cap?
Rocket Pharmaceuticals’s market cap is $1.12B.
When is Rocket Pharmaceuticals’s upcoming earnings report date?
Rocket Pharmaceuticals’s upcoming earnings report date is Mar 06, 2025 which is in 32 days.
How were Rocket Pharmaceuticals’s earnings last quarter?
Rocket Pharmaceuticals released its earnings results on Nov 07, 2024. The company reported -€0.682 earnings per share for the quarter, beating the consensus estimate of -€0.721 by €0.038.
Is Rocket Pharmaceuticals overvalued?
According to Wall Street analysts Rocket Pharmaceuticals’s price is currently Undervalued.
Does Rocket Pharmaceuticals pay dividends?
Rocket Pharmaceuticals does not currently pay dividends.
What is Rocket Pharmaceuticals’s EPS estimate?
Rocket Pharmaceuticals’s EPS estimate is -0.68.
How many shares outstanding does Rocket Pharmaceuticals have?
Rocket Pharmaceuticals has 106,337,080 shares outstanding.
What happened to Rocket Pharmaceuticals’s price movement after its last earnings report?
Rocket Pharmaceuticals reported an EPS of -€0.682 in its last earnings report, beating expectations of -€0.721. Following the earnings report the stock price went down -2.376%.
Which hedge fund is a major shareholder of Rocket Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:9IP1
---
Rocket Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€41.26 (319.78% Upside)
€41.26 (319.78% Upside)
Blogger Sentiment
Bullish
DE:9IP1 Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $311.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-61.54%
12-Months-Change
Fundamentals
Return on Equity
-59.27%
Trailing 12-Months
Asset Growth
-34.25%
Trailing 12-Months
Company Description
Rocket Pharmaceuticals
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of first-in-class gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector (LVV) and adeno-associated viral vector (AAV) gene therapy platforms. The firm's clinical program is a LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded in 1999 and is headquartered in New York, NY.
---
9IP1 Stock 12 Month Forecast
Average Price Target
€41.26
▲(319.78% Upside)
Technical Analysis
Sangamo Biosciences
―
Bluebird Bio
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering 9IP1
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+11.41%
reiterated a buy rating 3 months ago
Copying Greg Harrison's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +11.41% per trade.
---